Does DARATUMUMAB Cause Injection site extravasation? 20 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 20 reports of Injection site extravasation have been filed in association with DARATUMUMAB (DARZALEX). This represents 0.1% of all adverse event reports for DARATUMUMAB.
20
Reports of Injection site extravasation with DARATUMUMAB
0.1%
of all DARATUMUMAB reports
0
Deaths
0
Hospitalizations
How Dangerous Is Injection site extravasation From DARATUMUMAB?
Of the 20 reports.
Is Injection site extravasation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DARATUMUMAB. However, 20 reports have been filed with the FAERS database.
What Other Side Effects Does DARATUMUMAB Cause?
Plasma cell myeloma (2,980)
Infusion related reaction (2,557)
Off label use (2,494)
Pneumonia (1,450)
Neutropenia (1,351)
Drug ineffective (1,110)
Thrombocytopenia (1,089)
Death (1,088)
Pyrexia (1,032)
Dyspnoea (996)
What Other Drugs Cause Injection site extravasation?
EXENATIDE (2,320)
ETANERCEPT (1,139)
ADALIMUMAB (381)
SEMAGLUTIDE (342)
VEDOLIZUMAB (237)
SOMATROPIN (230)
REGADENOSON (226)
RITUXIMAB (215)
EVOLOCUMAB (188)
DUPILUMAB (170)
Which DARATUMUMAB Alternatives Have Lower Injection site extravasation Risk?
DARATUMUMAB vs DARATUMUMAB\HYALURONIDASE-FIHJ
DARATUMUMAB vs DARBEPOETIN ALFA
DARATUMUMAB vs DARIDOREXANT
DARATUMUMAB vs DARIFENACIN HYDROBROMIDE
DARATUMUMAB vs DAROLUTAMIDE